The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels

Inclusion criteria

• Male or female, age > 18 years
• Triglycerides ≥ 200 mg/dL and < 500 mg/dL
• Ability to give written informed consent

Exclusion criteria

• Female patient who are pregnant or breastfeeding or planning to become pregnant
• Fasting plasma glucose (FPG) levels > 110 mg/dL
• Type 2 diabetes mellitus that is poorly controlled (glycosylated hemoglobin [HbAlc ] >8.0%
• Patients who are under use of lipid altering drugs excluding use of Simvastatin, Atorvastatin, and Rosovastatin for 6 weeks or more
• Patients who are under use of products containing omega-3 fatty acids or other dietary supplements with potential lipid altering effects
• History of bariatric surgery or currently on weight loss drugs.
• Uncontrolled hypertension (BP>140/90)
• Subjects with secondary causes of hypertriglyceridemia: alcoholism, dysglobulinemia, thyroid disease that is poorly controlled (TSH<0.35 or TSH>5.5)
• Subjects with an abnormal level of liver enzymes (twice the normal level)
• Suffered from ischemic event such as myocardial infarction, cerebrovascular accident and angina pectoris in the last 6 months
• Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins such as cushing syndrome
• Gastrointestinal disease that may influence lipid metabolism such as celiac, crohn, colitis or other malabsorption problem
• Subjects who have had any malignancy. Subjects who have had basal cell carcinoma that have been disease free for at least 3 years are eligible for the study.
• Consumption of one fish serving (200 grams) or sea food x2 a week or more.
• HIV infection by history
• History of hypersensitivity or allergy to fish, fish oil or soy
• BMI≥35
• Weight change > 3 kg during the run-in period
• Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the patient